Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 35

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 35
---
 Attn: Ian Huen telephone: +44 20 80929299. xi PROSPECTUS SUMMARY This summary highlights selected information from this proxy statement/prospectus and may not contain all of the information that is important to you. To better understand the Merger and the proposals being considered at the Special Meeting, you should read this entire proxy statement/prospectus carefully, including the Merger Agreement and the other annexes to which you are referred in this proxy statement/prospectus, and the documents incorporated by reference therein. For more information, please see the section titled“ Where You Can Find More Information” . Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the proposed reverse split described in Proposal No. 1 of this proxy statement/prospectus. The Parties Aptorum Aptorum is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum now focuses all of its efforts on R&D; it no longer provides any clinical services. As of December 31, 2024 and the date hereof, it only operates in one segment. Aptorum’s goal is to develop a broad range of novel and repurposed therapeutics and diagnostics technology across a wide range of disease/therapeutic areas. Key components of its strategy for achieving this goal include: (for detailsof Aptorum’s strategy, See “Information about Aptorum — Aptorum’s Strategy”) •Developing therapeutic and diagnostic innovations across a wide range of disease/therapeutic areas; •Selectively expanding Aptorum’s portfolio with potential products that may be able to attain orphan drug designation and/or satisfy current unmet medical needs; •Collaborating with leading academic institutions and CROs; •Expanding Aptorum’s in -housepharmaceutical development center; •Leveraging Aptorum’s management’s expertise, experience and commercial networks; •Obtaining and leveraging government grants to fund project development. Aptorum’s Lead Projects are ALS -4and SACT -1. ALS -4is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body’s systems. These products of bacterial genes are referred to as “virulence expression.” Targeting bacterial virulence is an alternative approach